What is Wedbush’s Estimate for RCUS FY2029 Earnings?
Research analysts at Wedbush issued their FY2029 EPS estimates for shares of Arcus Biosciences in a note issued to investors ...
These Analysts Just Made A Decent Downgrade To Their Arcus Biosciences, Inc. (NYSE:RCUS) EPS Forecasts
One thing we could say about the analysts on Arcus Biosciences, Inc. (NYSE:RCUS) - they aren't optimistic, having just made a major negative revision to their near-term (statutory) forecasts for the ...
FierceBiotech4d
Gilead loses interest in Arcus' kidney cancer rival to Merck's Welireg
Gilead Sciences has defied analysts’ expectations by passing on its chance to license Arcus Biosciences’ potential rival to Merck & Co.’s kidney cancer drug Welireg.
BioPharma Dive2d
Sanofi reaches consumer health deal; Supernus antidepressant fails study
The pharma signed an agreement handing PE firm CD&R a 50% stake in its Capella unit. Elsewhere, Gilead and Ultragenyx secured ...
Arcus says new data demonstrated ‘best-in-class potential’ for casdatifan
Arcus Biosciences (RCUS) presented new data for casdatifan, a HIF-2a inhibitor with best-in-class potential, in an oral plenary session by Dr. Toni K. Choueiri, Dana-Farber Cancer Institute, at the ...
BioSpace3d
Gilead Passes on Option for Arcus’ Cancer Drug Despite Strong Early Data
The news comes on the heels of promising Phase I/Ib data, which point to the potential of casdatifan as a more effective ...
Contract Pharma4d
Arcus Regains Rights to Casdatifan
Arcus Biosciences, Inc. has regained ownership of casdatifan, a potential treatment for clear cell renal cell carcinoma (ccRCC), after Gilead’s time-limited exclusive option rights to casdatifan ...
Precision BioSciences Announces Initial Safety and Antiviral Activity of PBGENE-HBV in the ELIMINATE-B Clinical Trial
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases ...